Drug Trial Radar · NCT02688933
A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
638
Actual
Start
May 5, 2016
Primary completion
Jun 19, 2017
Study completion Jun 19, 2017
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus. Secondary Objective: To demonstrate that treatment with HOE901-U300 compared to Lantus provides: * Lower incidence rate of nocturnal symptomatic hypoglycemia; * Better glucose control coverage during the last hours of CGM before next basal-insulin dosing; * Less variability in CGM profile.
Conditions
- Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin Glargine 300 U/ml)Drug
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Lantus (Insulin Glargine 100 U/ml)Drug
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Mandated back ground therapyDrug
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGMTime frame: During Week 15 and/or 16
Locations
100 sites in 2 countries. Site status is shown where the registry gives one.
Investigational Site Number 840-151
Little Rock, Arkansas
Investigational Site Number 840-071
Concord, California
Investigational Site Number 840-149
Escondido, California
Investigational Site Number 840-004
Fresno, California
Investigational Site Number 840-110
Greenbrae, California
Investigational Site Number 840-124
La Jolla, California
Investigational Site Number 840-030
La Mesa, California
Investigational Site Number 840-044
Los Angeles, California
Investigational Site Number 840-022
Los Angeles, California
Investigational Site Number 840-129
Los Gatos, California
Investigational Site Number 840-024
Northridge, California
Investigational Site Number 840-069
Pomona, California
Investigational Site Number 840-090
Pomona, California
Investigational Site Number 840-132
Rolling Hills Estates, California
Investigational Site Number 840-130
San Jose, California
Investigational Site Number 840-055
San Ramon, California
Investigational Site Number 840-028
Santa Barbara, California
Investigational Site Number 840-063
Tarzana, California
Investigational Site Number 840-138
Tustin, California
Investigational Site Number 840-016
Ventura, California
Investigational Site Number 840-039
Denver, Colorado
Investigational Site Number 840-021
Denver, Colorado
Investigational Site Number 840-070
Denver, Colorado
Investigational Site Number 840-046
Englewood, Colorado
Investigational Site Number 840-072
Coral Gables, Florida
Investigational Site Number 840-133
Hialeah, Florida
Investigational Site Number 840-137
Maitland, Florida
Investigational Site Number 840-049
Miami, Florida
Investigational Site Number 840-076
Miami, Florida
Investigational Site Number 840-023
New Port Richey, Florida
Investigational Site Number 840-053
Ocoee, Florida
Investigational Site Number 840-112
Ormond Beach, Florida
Investigational Site Number 840-018
Palm Harbor, Florida
Investigational Site Number 840-047
Port Charlotte, Florida
Investigational Site Number 840-114
Tampa, Florida
Investigational Site Number 840-036
West Palm Beach, Florida
Investigational Site Number 840-001
Atlanta, Georgia
Investigational Site Number 840-064
Columbus, Georgia
Investigational Site Number 840-012
Lawrenceville, Georgia
Investigational Site Number 840-008
Roswell, Georgia
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.